Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1981 1
1984 1
1985 3
1987 1
1988 4
1989 7
1990 4
1991 21
1992 18
1993 34
1994 40
1995 64
1996 63
1997 129
1998 184
1999 251
2000 355
2001 422
2002 476
2003 490
2004 595
2005 633
2006 639
2007 617
2008 650
2009 722
2010 778
2011 947
2012 994
2013 1093
2014 1303
2015 1345
2016 1139
2017 1163
2018 1066
2019 354
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

15,053 results
Results by year
Filters applied: . Clear all
Page 1
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.
Falade-Nwulia O, et al. Ann Intern Med 2017 - Review. PMID 28319996 Free PMC article.
BACKGROUND: Rapid improvements in hepatitis C virus (HCV) therapy have led to the approval of multiple oral direct-acting antiviral (DAA) regimens by the U.S. Food and Drug Administration (FDA) for treatment of chronic HCV infection. PURPOSE: To summarize published literature on the efficacy and safety of oral DAAs for treatment of persons with chronic HCV infection. ...
BACKGROUND: Rapid improvements in hepatitis C virus (HCV) therapy have led to the approval of multiple oral direct-acti …
Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
Rossi C, et al. J Hepatol 2018. PMID 30142429
BACKGROUND & AIMS: Direct-acting antiviral therapies (DAA) are an important tool for hepatitis C virus (HCV) elimination. However, reinfection among people who inject drugs (PWID) may hamper elimination targets. ...LAY SUMMARY: Direct-acting antivirals are an effective tool for the treatment of hepatitis C virus, enabling the elimination of the virus. ...
BACKGROUND & AIMS: Direct-acting antiviral therapies (DAA) are an important tool for hepatitis C virus (HCV) elimination. …
Hepatitis C - New drugs and treatment prospects.
Zając M, et al. Eur J Med Chem 2019 - Review. PMID 30685524
Hepatitis C virus (HCV) affects approx. 3% of the world's population and accounts for ca 300 000 deaths per year. 80% of individuals with HCV develop chronic symptoms which, when untreated, may cause cirrhosis (27%) or hepatocellular carcinoma (25%). The hepatitis C virus is a (+)ssRNA enveloped virus of the family Flaviviridae. Seven major HCV genotypes and their subtypes (a, b) have been identified. ...
Hepatitis C virus (HCV) affects approx. 3% of the world's population and accounts for ca 300 000 deaths per year. 80% of indiv
[The news in hepatitis C therapy].
Dikopoulos N, et al. MMW Fortschr Med 2017. PMID 29086258 German.
Towards curative therapy of chronic viral hepatitis.
Bartenschlager R, et al. Z Gastroenterol 2019. PMID 30641605
A major step forward has been the development of curative antiviral therapy for chronic hepatitis C. In the case of hepatitis D virus, new drug candidates have been developed that should receive conditional approval very soon. For chronic hepatitis B, development is lagging behind but thanks to a re-emerging interest of pharmaceutical industry that was triggered by the success of hepatitis C therapy and the availability of novel infection systems, new attempts towards curative approaches for this highly prevalent infection are undertaken. ...
A major step forward has been the development of curative antiviral therapy for chronic hepatitis C. In the case of …
[Present and future of therapy against hepatitis C].
Jaspe RC, et al. Invest Clin 2016 - Review. PMID 27382805 Spanish.
Around 3% of the human population is infected with hepatitis C virus (HCV) and 70-80% of these individuals develop a chronic infection. ...With such treatment, the eradication of the disease would be feasible, although drug costs are high. Host target therapy represents an emerging alternative, based on the understanding of host factors involved in the HCV infection. ...
Around 3% of the human population is infected with hepatitis C virus (HCV) and 70-80% of these individuals develop a chronic i …
A new era of therapy for hepatitis C virus infection.
Nyalakonda H and Utay NS. Curr Opin Infect Dis 2015 - Review. PMID 26203851
PURPOSE OF REVIEW: Previous treatments with pegylated interferon (PEG-IFN) and ribavirin for hepatitis C virus (HCV) infection resulted in significant adverse events and low cure rates, even with the addition of first-generation protease inhibitors. ...
PURPOSE OF REVIEW: Previous treatments with pegylated interferon (PEG-IFN) and ribavirin for hepatitis C virus (HCV) infection …
15,053 results
Jump to page
Feedback